Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology/Shanghai Biomabs Pharmaceutical

Next Previous
X
Search
Drug Profile

Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology/Shanghai Biomabs Pharmaceutical

Alternative Names: Aomaishu; CMAB-007; Omalizumab alpha; Omalizumab alpha - Shanghai Zhangjiang Biotechnology/Shanghai Biomabs Pharmaceutical

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology
  • Developer Mabpharm; Shanghai Biomabs Pharmaceuticals
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic asthma; Urticaria

Most Recent Events

  • 18 Jun 2024 Phase-III clinical trials in Urticaria (Treatment-experienced, In adolescents, In adults, In the elderly) in China (SC) (NCT06365879)
  • 15 Apr 2024 Taizhou Mabtech Pharmaceutical plans a phase III trial for Urticaria (SC, Injection) (NCT06365879)
  • 13 Sep 2022 Taizhou Mabtech Pharmaceutical completes a phase I trial for Asthma (In volunteers) in China (SC, Injection) (NCT05897008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top